Details of the Drug

General Information of Drug (ID: DMSI5CB)

Drug Name
Chloroquine
Synonyms
Amokin; Aralen; Aralen HCl; Arechin; Arechine; Arequin; Arolen; Arthrochin; Artrichin; Avlochlor; Avloclor; Bemaco; Bemaphate; Bemasulph; Benaquin; Bipiquin; CU-01000012392-2; Capquin; Chemochin; Chingamin; Chloraquine; Chlorochin; Chlorochine; Chlorochinum; Chloroin; Chloroquin; Chloroquina; Chloroquine (USP/INN); Chloroquine (VAN); Chloroquine Bis-Phosphoric Acid; Chloroquine FNA (TN); Chloroquine [USAN:INN:BAN]; Chloroquine phosphate; Chloroquinium; Chloroquinum; Chloroquinum [INN-Latin]; Chlorquin; Cidanchin; Clorochina; Clorochina [DCIT]; Cloroquina; Cloroquina [INN-Spanish]; Cocartrit; Dawaquin (TN); Delagil; Dichinalex; Elestol; Gontochin; Gontochin phosphate; Heliopar; Imagon; Ipsen 225; Iroquine; Khingamin; Klorokin; Lapaquin; Malaquin; Malaquin (*Diphosphate*); Malaren; Malarex; Mesylith; Miniquine; Neochin; Nivachine; Nivaquine B; Pfizerquine; Quinachlor; Quinagamin; Quinagamine; Quinercyl; Quingamine; Quinilon; Quinoscan; RP 3377; RP-3377; Resochen; Resochin; Resochin (TN); Resoquina; Resoquine; Reumachlor; Reumaquin; Rivoquine; Ro 01-6014/N2; Ronaquine; Roquine; SN 6718; SN-7618; ST 21; ST 21 (pharmaceutical); Sanoquin; Silbesan;Siragan; Solprina; Sopaquin; Tanakan; Tanakene; Tresochin; Trochin; W 7618;WIN 244
Indication
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Approved [1], [2]
Therapeutic Class
Antimalarials
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 319.9
Topological Polar Surface Area (xlogp) 4.6
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability
80% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 4.1 mL/min/kg [5]
Elimination
61% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 570 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 46.89244 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.43% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 140 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 100 mg/mL [3]
Chemical Identifiers
Formula
C18H26ClN3
IUPAC Name
4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine
Canonical SMILES
CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
InChI
InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)
InChIKey
WHTVZRBIWZFKQO-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2719
ChEBI ID
CHEBI:3638
CAS Number
54-05-7
DrugBank ID
DB00608
TTD ID
D09EGZ
VARIDT ID
DR00572
INTEDE ID
DR0301
ACDINA ID
D00121

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Duffy antigen chemokine receptor (ACKR1) TTKY2NS ACKR1_HUMAN Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Chloroquine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Chloroquine and Lumefantrine. Malaria [1F40-1F45] [72]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Chloroquine and Halofantrine. Malaria [1F40-1F45] [73]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Chloroquine and Primaquine. Malaria [1F40-1F45] [74]
Coadministration of a Drug Treating the Disease Different from Chloroquine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Chloroquine and Repaglinide. Acute diabete complication [5A2Y] [75]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Chloroquine and Glibenclamide. Acute diabete complication [5A2Y] [75]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Chloroquine and Tolazamide. Acute diabete complication [5A2Y] [75]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Chloroquine and Nateglinide. Acute diabete complication [5A2Y] [75]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Chloroquine and Insulin-glulisine. Acute diabete complication [5A2Y] [75]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Chloroquine and Insulin-aspart. Acute diabete complication [5A2Y] [76]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Chloroquine and Glipizide. Acute diabete complication [5A2Y] [75]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Chloroquine and Ivosidenib. Acute myeloid leukaemia [2A60] [77]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Chloroquine and Midostaurin. Acute myeloid leukaemia [2A60] [74]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Chloroquine and Idarubicin. Acute myeloid leukaemia [2A60] [74]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Chloroquine and Daunorubicin. Acute myeloid leukaemia [2A60] [78]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Arn-509. Acute myeloid leukaemia [2A60] [79]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Chloroquine and Gilteritinib. Acute myeloid leukaemia [2A60] [74]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Chloroquine and Oliceridine. Acute pain [MG31] [74]
Mitotane DMU1GX0 Moderate Increased metabolism of Chloroquine caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [72]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Chloroquine and Galantamine. Alzheimer disease [8A20] [80]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Chloroquine and Rivastigmine. Alzheimer disease [8A20] [80]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Chloroquine and Donepezil. Alzheimer disease [8A20] [80]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Chloroquine and Ivabradine. Angina pectoris [BA40] [79]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Chloroquine and Bepridil. Angina pectoris [BA40] [80]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Chloroquine and Dronedarone. Angina pectoris [BA40] [80]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Chloroquine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [74]
Methylphenobarbital DMDSWAG Moderate Antagonize the effect of Chloroquine when combined with Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [72]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Chloroquine and Cilostazol. Arterial occlusive disease [BD40] [74]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Chloroquine and Posaconazole. Aspergillosis [1F20] [74]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Levalbuterol. Asthma [CA23] [81]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Chloroquine and Terbutaline. Asthma [CA23] [82]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Pirbuterol. Asthma [CA23] [82]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Salbutamol. Asthma [CA23] [81]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Chloroquine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [74]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Chloroquine and Desipramine. Attention deficit hyperactivity disorder [6A05] [74]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Chloroquine and Ofloxacin. Bacterial infection [1A00-1C4Z] [74]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Chloroquine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [72]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Chloroquine and Clarithromycin. Bacterial infection [1A00-1C4Z] [74]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Chloroquine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [80]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Chloroquine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [83]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Chloroquine and Norfloxacin. Bacterial infection [1A00-1C4Z] [74]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Chloroquine and Levofloxacin. Bacterial infection [1A00-1C4Z] [74]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Chloroquine caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [72]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Chloroquine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [74]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Chloroquine and Telithromycin. Bacterial infection [1A00-1C4Z] [74]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Chloroquine and Retigabine. Behcet disease [4A62] [74]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Loperamide. Bowel habit change [ME05] [84]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Chloroquine and Eribulin. Breast cancer [2C60-2C6Y] [74]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Chloroquine and Lapatinib. Breast cancer [2C60-2C6Y] [74]
Tucatinib DMBESUA Moderate Decreased metabolism of Chloroquine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [72]
Tamoxifen DMLB0EZ Major Increased risk of prolong QT interval by the combination of Chloroquine and Tamoxifen. Breast cancer [2C60-2C6Y] [74]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Chloroquine and Bosutinib. Breast cancer [2C60-2C6Y] [74]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Chloroquine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [82]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Chloroquine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [81]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Chloroquine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [82]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Chloroquine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [82]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Chloroquine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [82]
Levetiracetam DMTGDN8 Moderate Antagonize the effect of Chloroquine when combined with Levetiracetam. Chronic pain [MG30] [72]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Chloroquine and Isoproterenol. Conduction disorder [BC63] [81]
Atracurium DM42HXN Moderate Additive neuromuscular blocking effects by the combination of Chloroquine and Atracurium. Corneal disease [9A76-9A78] [85]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Chloroquine and Mivacurium. Corneal disease [9A76-9A78] [85]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Chloroquine and Halothane. Corneal disease [9A76-9A78] [74]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Chloroquine and Pancuronium. Corneal disease [9A76-9A78] [85]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Propofol. Corneal disease [9A76-9A78] [86]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Chloroquine and Sevoflurane. Corneal disease [9A76-9A78] [74]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Chloroquine and Probucol. Coronary atherosclerosis [BA80] [74]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Chloroquine and Clofazimine. Crohn disease [DD70] [74]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Chloroquine and Mifepristone. Cushing syndrome [5A70] [80]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Chloroquine and Pasireotide. Cushing syndrome [5A70] [74]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Chloroquine and Osilodrostat. Cushing syndrome [5A70] [74]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Chloroquine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [72]
MK-8228 DMOB58Q Moderate Decreased metabolism of Chloroquine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [72]
Aprepitant DM053KT Moderate Decreased metabolism of Chloroquine caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [72]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Chloroquine and Sertraline. Depression [6A70-6A7Z] [74]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Chloroquine and Trimipramine. Depression [6A70-6A7Z] [74]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Chloroquine and Escitalopram. Depression [6A70-6A7Z] [80]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Chloroquine and Clomipramine. Depression [6A70-6A7Z] [74]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Chloroquine and Trazodone. Depression [6A70-6A7Z] [74]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Chloroquine and Doxepin. Depression [6A70-6A7Z] [74]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Chloroquine and Maprotiline. Depression [6A70-6A7Z] [74]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Chloroquine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [74]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Chloroquine and Deutetrabenazine. Dystonic disorder [8A02] [74]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Chloroquine and Ingrezza. Dystonic disorder [8A02] [74]
Zonisamide DM0DTF7 Moderate Antagonize the effect of Chloroquine when combined with Zonisamide. Epilepsy/seizure [8A61-8A6Z] [72]
Primidone DM0WX6I Moderate Increased metabolism of Chloroquine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [72]
Felbamate DM1V5ZS Moderate Antagonize the effect of Chloroquine when combined with Felbamate. Epilepsy/seizure [8A61-8A6Z] [72]
Oxcarbazepine DM5PU6O Moderate Antagonize the effect of Chloroquine when combined with Oxcarbazepine. Epilepsy/seizure [8A61-8A6Z] [72]
Methsuximide DM6L5VO Moderate Antagonize the effect of Chloroquine when combined with Methsuximide. Epilepsy/seizure [8A61-8A6Z] [72]
Gabapentin DM6T924 Moderate Antagonize the effect of Chloroquine when combined with Gabapentin. Epilepsy/seizure [8A61-8A6Z] [72]
Tiagabine DMKSQG0 Moderate Antagonize the effect of Chloroquine when combined with Tiagabine. Epilepsy/seizure [8A61-8A6Z] [72]
Stiripentol DMMSDOY Moderate Antagonize the effect of Chloroquine when combined with Stiripentol. Epilepsy/seizure [8A61-8A6Z] [72]
Phenacemide DMOHS9P Moderate Antagonize the effect of Chloroquine when combined with Phenacemide. Epilepsy/seizure [8A61-8A6Z] [72]
Fosphenytoin DMOX3LB Moderate Antagonize the effect of Chloroquine when combined with Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [72]
Paramethadione DMR5ZUP Moderate Antagonize the effect of Chloroquine when combined with Paramethadione. Epilepsy/seizure [8A61-8A6Z] [72]
Brivaracetam DMSEPK8 Moderate Antagonize the effect of Chloroquine when combined with Brivaracetam. Epilepsy/seizure [8A61-8A6Z] [72]
Lacosamide DMVM6QR Moderate Antagonize the effect of Chloroquine when combined with Lacosamide. Epilepsy/seizure [8A61-8A6Z] [72]
Rufinamide DMWE60C Moderate Antagonize the effect of Chloroquine when combined with Rufinamide. Epilepsy/seizure [8A61-8A6Z] [72]
Ethotoin DMXWOCP Moderate Antagonize the effect of Chloroquine when combined with Ethotoin. Epilepsy/seizure [8A61-8A6Z] [72]
Phenobarbital DMXZOCG Moderate Antagonize the effect of Chloroquine when combined with Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [72]
Eslicarbazepine DMZREFQ Moderate Antagonize the effect of Chloroquine when combined with Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [72]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Chloroquine and Solifenacin. Functional bladder disorder [GC50] [74]
Tolterodine DMSHPW8 Minor Decreased metabolism of Chloroquine caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [87]
Itraconazole DMCR1MV Moderate Decreased metabolism of Chloroquine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [72]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Chloroquine and Pentamidine. Fungal infection [1F29-1F2F] [74]
Terbinafine DMI6HUW Moderate Decreased metabolism of Chloroquine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [88]
Ketoconazole DMPZI3Q Major Increased risk of prolong QT interval by the combination of Chloroquine and Ketoconazole. Fungal infection [1F29-1F2F] [74]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Chloroquine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [74]
Acetazolamide DM1AF5U Moderate Antagonize the effect of Chloroquine when combined with Acetazolamide. Glaucoma [9C61] [72]
Carvedilol DMHTEAO Minor Decreased metabolism of Chloroquine caused by Carvedilol mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [89]
Boceprevir DMBSHMF Moderate Decreased metabolism of Chloroquine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [72]
Telaprevir DMMRV29 Moderate Decreased metabolism of Chloroquine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [72]
Rifampin DMA8J1G Moderate Increased metabolism of Chloroquine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [72]
Rifapentine DMCHV4I Moderate Increased metabolism of Chloroquine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [72]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Chloroquine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [90]
Delavirdine DM3NF5G Moderate Decreased metabolism of Chloroquine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Chloroquine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Chloroquine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [74]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Chloroquine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Chloroquine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [91]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Chloroquine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [92]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Chloroquine and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [93]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Chloroquine and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [78]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Chloroquine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [74]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Chloroquine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Darunavir DMN3GCH Moderate Decreased metabolism of Chloroquine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Atazanavir DMSYRBX Moderate Decreased metabolism of Chloroquine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Gemfibrozil DMD8Q3J Moderate Decreased metabolism of Chloroquine caused by Gemfibrozil mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [72]
Acebutolol DM0TI4U Minor Decreased metabolism of Chloroquine caused by Acebutolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [89]
Penbutolol DM4ES8F Minor Decreased metabolism of Chloroquine caused by Penbutolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [89]
Verapamil DMA7PEW Moderate Decreased metabolism of Chloroquine caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [72]
Quinapril DMR8H31 Moderate Decreased absorption of Chloroquine due to formation of complexes caused by Quinapril. Hypertension [BA00-BA04] [79]
Conivaptan DM1V329 Moderate Decreased metabolism of Chloroquine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [72]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Chloroquine and Polyethylene glycol. Irritable bowel syndrome [DD91] [80]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Chloroquine and Crizotinib. Lung cancer [2C25] [74]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Chloroquine and Porfimer Sodium. Lung cancer [2C25] [94]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Chloroquine and Ceritinib. Lung cancer [2C25] [74]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Chloroquine and Osimertinib. Lung cancer [2C25] [74]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Chloroquine and Selpercatinib. Lung cancer [2C25] [74]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Chloroquine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [74]
Idelalisib DM602WT Moderate Decreased metabolism of Chloroquine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [72]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Chloroquine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [95]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Chloroquine and Vemurafenib. Melanoma [2C30] [80]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Chloroquine and LGX818. Melanoma [2C30] [74]
Exjade DMHPRWG Moderate Decreased metabolism of Chloroquine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [72]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Chloroquine due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [80]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Chloroquine and Panobinostat. Multiple myeloma [2A83] [96]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Chloroquine and Thalidomide. Multiple myeloma [2A83] [72]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Chloroquine and Siponimod. Multiple sclerosis [8A40] [72]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Chloroquine and Fingolimod. Multiple sclerosis [8A40] [80]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Chloroquine and Ozanimod. Multiple sclerosis [8A40] [97]
Rifabutin DM1YBHK Moderate Increased metabolism of Chloroquine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [72]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Chloroquine and Romidepsin. Mycosis fungoides [2B01] [74]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Chloroquine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [72]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Chloroquine and Nilotinib. Myeloproliferative neoplasm [2A20] [80]
Imatinib DM7RJXL Moderate Decreased metabolism of Chloroquine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [72]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Chloroquine and Dasatinib. Myeloproliferative neoplasm [2A20] [74]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Chloroquine and Granisetron. Nausea/vomiting [MD90] [74]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Chloroquine and Dolasetron. Nausea/vomiting [MD90] [74]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Chloroquine and Ondansetron. Nausea/vomiting [MD90] [74]
E-2007 DMJDYNQ Moderate Antagonize the effect of Chloroquine when combined with E-2007. Neuropathy [8C0Z] [72]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Chloroquine and Bupropion. Nicotine use disorder [6C4A] [98]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Chloroquine and Entrectinib. Non-small cell lung cancer [2C25] [74]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Chloroquine and Levomethadyl Acetate. Opioid use disorder [6C43] [79]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Chloroquine and Lofexidine. Opioid use disorder [6C43] [74]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Chloroquine and Rucaparib. Ovarian cancer [2C73] [74]
Dextropropoxyphene DM23HCX Major Increased risk of prolong QT interval by the combination of Chloroquine and Dextropropoxyphene. Pain [MG30-MG3Z] [78]
Prilocaine DMI7DZ2 Major Increased risk of methemoglobinemia by the combination of Chloroquine and Prilocaine. Pain [MG30-MG3Z] [99]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Chloroquine and Triclabendazole. Parasitic worm infestation [1F90] [74]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Chloroquine and Pimavanserin. Parkinsonism [8A00] [74]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Chloroquine and Apomorphine. Parkinsonism [8A00] [74]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Famotidine. Peptic ulcer [DA61] [72]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Chloroquine and Macimorelin. Pituitary gland disorder [5A60-5A61] [100]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Chloroquine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [72]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Ritodrine. Preterm labour/delivery [JB00] [82]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Degarelix. Prostate cancer [2C82] [79]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Chloroquine and ABIRATERONE. Prostate cancer [2C82] [79]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Nilutamide. Prostate cancer [2C82] [79]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Enzalutamide. Prostate cancer [2C82] [79]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Relugolix. Prostate cancer [2C82] [79]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Bicalutamide. Prostate cancer [2C82] [79]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Chloroquine and Levomepromazine. Psychotic disorder [6A20-6A25] [74]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Chloroquine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [101]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Chloroquine and Quetiapine. Schizophrenia [6A20] [74]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Chloroquine and Mesoridazine. Schizophrenia [6A20] [80]
Thioridazine DM35M8J Major Decreased metabolism of Chloroquine caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [102]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Chloroquine caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [72]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Chloroquine and Iloperidone. Schizophrenia [6A20] [74]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Chloroquine and Paliperidone. Schizophrenia [6A20] [74]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Chloroquine and Perphenazine. Schizophrenia [6A20] [74]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Chloroquine and Trifluoperazine. Schizophrenia [6A20] [74]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Chloroquine and Amisulpride. Schizophrenia [6A20] [74]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Chloroquine and Asenapine. Schizophrenia [6A20] [74]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Chloroquine and Pimozide. Schizophrenia [6A20] [79]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Chloroquine and Vardenafil. Sexual dysfunction [HA00-HA01] [74]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Chloroquine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [72]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Chloroquine and LEE011. Solid tumour/cancer [2A00-2F9Z] [74]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Chloroquine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [80]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Chloroquine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [79]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Chloroquine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [74]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Chloroquine and Pitolisant. Somnolence [MG42] [74]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Chloroquine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [74]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Chloroquine and Adenosine. Supraventricular tachyarrhythmia [BC81] [80]
Clopidogrel DMOL54H Moderate Decreased metabolism of Chloroquine caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [72]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Chloroquine and Lenvatinib. Thyroid cancer [2D10] [74]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Chloroquine and Cabozantinib. Thyroid cancer [2D10] [74]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Chloroquine and Papaverine. Tonus and reflex abnormality [MB47] [103]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Chloroquine and Vecuronium. Tonus and reflex abnormality [MB47] [85]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Chloroquine and Tizanidine. Tonus and reflex abnormality [MB47] [74]
Rocuronium DMY9BMK Moderate Additive neuromuscular blocking effects by the combination of Chloroquine and Rocuronium. Tonus and reflex abnormality [MB47] [85]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Chloroquine and Tacrolimus. Transplant rejection [NE84] [74]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Chloroquine and Tolbutamide. Type 2 diabetes mellitus [5A11] [75]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Chloroquine and Chlorpropamide. Type 2 diabetes mellitus [5A11] [75]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Chloroquine and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [75]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Chloroquine and Insulin degludec. Type-1/2 diabete [5A10-5A11] [75]
Astemizole DM2HN6Q Major Increased risk of prolong QT interval by the combination of Chloroquine and Astemizole. Vasomotor/allergic rhinitis [CA08] [74]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Chloroquine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [78]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Chloroquine and Procainamide. Ventricular tachyarrhythmia [BC71] [80]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Chloroquine and Propafenone. Ventricular tachyarrhythmia [BC71] [74]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Chloroquine and Flecainide. Ventricular tachyarrhythmia [BC71] [74]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Chloroquine and Amiodarone. Ventricular tachyarrhythmia [BC71] [80]
⏷ Show the Full List of 216 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
D&C red no. 27 E00381 83511 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Quinoline yellow WS E00309 24671 Colorant
Calcium hydrogenphosphate E00294 24441 Diluent
Calcium stearate E00244 15324 lubricant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 16 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Chloroquine 250 mg tablet 250 mg Oral Tablet Oral
Chloroquine 500 mg tablet 500 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5535).
2 Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
9 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
10 Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003 Aug;26(8):631-7.
11 Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998 Mar;45(3):315-7.
12 In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003 Jun;31(6):748-54.
13 Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health. 2005 Dec;10(12):1271-3.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
24 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
25 Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
26 Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
27 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
28 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
29 A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
30 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
31 Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
32 Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
33 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
34 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
35 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
36 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
37 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
38 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
39 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
40 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
41 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
42 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
43 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
44 Drug Interactions Flockhart Table
45 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
46 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
47 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
48 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
49 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
50 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
51 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
52 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
53 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
54 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
55 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
56 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
57 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
58 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
59 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
60 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
61 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
62 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
63 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
64 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
65 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
66 Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
67 Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
68 Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
69 FDA Drug Development and Drug Interactions
70 Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity. Drug Metab Dispos. 2018 May;46(5):592-599.
71 From control to eradication of malaria: the end of being stuck in second gear . Asian Pacific Journal of Tropical Medicine Volume 3, Issue 5, May 2010, Pages 412-420.
72 Cerner Multum, Inc. "Australian Product Information.".
73 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
74 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
75 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
76 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
77 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
78 Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine). Prasco Laboratories, Cincinnati, OH.
79 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
80 Canadian Pharmacists Association.
81 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
82 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
83 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
84 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
85 Multum Information Services, Inc. Expert Review Panel.
86 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
87 Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
88 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
89 Lancaster DL, Adio RA, Tai KK, Simooya OO, Broadhead GD, Tucker GT, Lennard MS "Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs." J Pharm Pharmacol 42 (1990): 267-71. [PMID: 1974295]
90 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
91 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
92 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
93 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
94 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
95 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
96 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
97 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
98 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
99 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
100 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
101 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
102 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
103 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]